1,184 reports of this reaction
3.3% of all BUSULFAN reports
#3 most reported adverse reaction
MUCOSAL INFLAMMATION is the #3 most commonly reported adverse reaction for BUSULFAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 1,184 FDA adverse event reports linking BUSULFAN to MUCOSAL INFLAMMATION. This represents approximately 3.3% of all 36,413 adverse event reports for this drug.
Patients taking BUSULFAN who experience mucosal inflammation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUCOSAL INFLAMMATION is moderately reported among BUSULFAN users, representing a notable but not dominant share of adverse events.
In addition to mucosal inflammation, the following adverse reactions have been reported for BUSULFAN:
The following drugs have also been linked to mucosal inflammation in FDA adverse event reports:
MUCOSAL INFLAMMATION has been reported as an adverse event in 1,184 FDA reports for BUSULFAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUCOSAL INFLAMMATION accounts for approximately 3.3% of all adverse event reports for BUSULFAN, making it one of the most commonly reported side effect.
If you experience mucosal inflammation while taking BUSULFAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.